{
  "docId": "019de073-b144-743c-94c4-bc5a80eb44df",
  "docSlug": "9540d42c57dd536e8cb82c97bd211004",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 50 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 15,
  "pageCount": 50,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a callout box to summarize the upcoming milestones for the company's pipeline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-b144-743c-94c4-bc5a80eb44df/15",
  "deckHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df",
  "deckJsonHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df.json",
  "deckAnchorHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.33,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "callout",
      "text": "Program Milestones remaining in 2022 include a product launch, data readout, and Phase 3 investigator meeting*:",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71a948a7-0717-4273-a52d-511a1070b1f0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.56,
        "x": 0.41,
        "y": 0.18
      },
      "kind": "list",
      "text": "XACIATO (clindamycin phosphate) vaginal gel, 2% (f/k/a DARE-BV1)\nCommercial launch in the U.S. in 4Q 2022\nOvaprene® (hormone-free monthly contraception)\nPivotal Phase 3 study investigator meeting 12/2022; recruitment initiation mid-2023*\nDARE-VVA1 (vaginal atrophy treatment for women with breast cancer)\nPhase 1/2 study topline data during 4Q-2022\nSildenafil Cream, 3.6% (female sexual arousal disorder)\nPhase 2b study enrollment expected to complete 4Q-2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "444b540c-bae1-4ddf-a98a-875cb41f0fe1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.51,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "*Currently anticipated timing",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ba907c8-520e-4c4b-a300-d3714093ec47",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.74,
        "x": 0.13,
        "y": 0.03
      },
      "kind": "title",
      "text": "Daré – Working to Accelerate Innovation in Women's Health",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18fc10a9-035a-4384-9f8e-c02f8632ce67",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}